Literature DB >> 26348590

Transcriptome Profiling Reveals Degree of Variability in Induced Pluripotent Stem Cell Lines: Impact for Human Disease Modeling.

Jens Schuster1, Jonatan Halvardson1, Laureanne Pilar Lorenzo1, Adam Ameur1, Maria Sobol1, Doroteya Raykova1, Göran Annerén1, Lars Feuk1, Niklas Dahl1.   

Abstract

Induced pluripotent stem cell (iPSC) technology has become an important tool for disease modeling. Insufficient data on the variability among iPSC lines derived from a single somatic parental cell line have in practice led to generation and analysis of several, usually three, iPSC sister lines from each parental cell line. We established iPSC lines from a human fibroblast line (HDF-K1) and used transcriptome sequencing to investigate the variation among three sister lines (iPSC-K1A, B, and C). For comparison, we analyzed the transcriptome of an iPSC line (iPSC-K5B) derived from a different fibroblast line (HDF-K5), a human embryonic stem cell (ESC) line (ESC-HS181), as well as the two parental fibroblast lines. All iPSC lines fulfilled stringent criteria for pluripotency. In an unbiased cluster analysis, all stem cell lines (four iPSCs and one ESC) clustered together as opposed to the parental fibroblasts. The transcriptome profiles of the three iPSC sister lines were indistinguishable from each other, and functional pathway analysis did not reveal any significant hits. In contrast, the expression profiles of the ESC line and the iPSC-K5B line were distinct from that of the sister lines iPSC-K1A, B, and C. Differentiation to embryoid bodies and subsequent analysis of germ layer markers in the five stem cell clones confirmed that the distribution of their expression profiles was retained. Taken together, our observations stress the importance of using iPSCs of different parental origin rather than several sister iPSC lines to distinguish disease-associated mechanisms from genetic background effects in disease modeling.

Entities:  

Mesh:

Year:  2015        PMID: 26348590     DOI: 10.1089/cell.2015.0009

Source DB:  PubMed          Journal:  Cell Reprogram        ISSN: 2152-4971            Impact factor:   1.987


  6 in total

1.  Examining FKBP5 mRNA expression in human iPSC-derived neural cells.

Authors:  Richard Lieberman; Henry R Kranzler; Eric S Levine; Jonathan Covault
Journal:  Psychiatry Res       Date:  2016-11-24       Impact factor: 3.222

2.  Uncompensated mitochondrial oxidative stress underlies heart failure in an iPSC-derived model of congenital heart disease.

Authors:  Xinxiu Xu; Kang Jin; Abha S Bais; Wenjuan Zhu; Hisato Yagi; Timothy N Feinstein; Phong K Nguyen; Joseph D Criscione; Xiaoqin Liu; Gisela Beutner; Kalyani B Karunakaran; Krithika S Rao; Haoting He; Phillip Adams; Catherine K Kuo; Dennis Kostka; Gloria S Pryhuber; Sruti Shiva; Madhavi K Ganapathiraju; George A Porter; Jiuann-Huey Ivy Lin; Bruce Aronow; Cecilia W Lo
Journal:  Cell Stem Cell       Date:  2022-04-07       Impact factor: 25.269

3.  Dysfunction telomeres in embryonic fibroblasts and cultured in vitro pluripotent stem cells of Rattus norvegicus (Rodentia, Muridae).

Authors:  Natalya S Zhdanova; Evgenia A Vaskova; Tatyana V Karamysheva; Julia M Minina; Nykolay B Rubtsov; Suren M Zakian
Journal:  Comp Cytogenet       Date:  2019-07-29       Impact factor: 1.800

Review 4.  Corneal cell therapy: with iPSCs, it is no more a far-sight.

Authors:  Koushik Chakrabarty; Rohit Shetty; Arkasubhra Ghosh
Journal:  Stem Cell Res Ther       Date:  2018-10-25       Impact factor: 6.832

5.  New Drug Discovery Paradigms for Retinal Diseases: A Focus on Retinal Organoids.

Authors:  Davis M Aasen; M Natalia Vergara
Journal:  J Ocul Pharmacol Ther       Date:  2019-05-06       Impact factor: 2.671

Review 6.  "Betwixt Mine Eye and Heart a League Is Took": The Progress of Induced Pluripotent Stem-Cell-Based Models of Dystrophin-Associated Cardiomyopathy.

Authors:  Davide Rovina; Elisa Castiglioni; Francesco Niro; Sara Mallia; Giulio Pompilio; Aoife Gowran
Journal:  Int J Mol Sci       Date:  2020-09-23       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.